ReviewFibrogenesis & tissue repair2016
Dipeptidyl peptidase-4 and kidney fibrosis in diabetes.
Review in Fibrogenesis & tissue repair, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 65 citations in OpenAlex.
- Protective Effects ofFood science & nutrition · 2025Article
- Preclinical pharmacological profiles of cofrogliptin, a novel and bi-weekly DPP-4 inhibitor.Frontiers in pharmacology · 2025Article
- New Insights into the Pleiotropic Actions of Dipeptidyl Peptidase-4 Inhibitors Beyond Glycaemic Control.TouchREVIEWS in endocrinology · 2024Review
- Integrated multi-omics profiling landscape of organising pneumonia.Clinical and translational medicine · 2024Article
- Linagliptin ameliorates tacrolimus-induced renal injury: role of Nrf2/HO-1 and HIF-1α/CTGF/PAI-1.Molecular biology reports · 2024Article
- Tissue fibrosis associated depletion of lipid-filled cells.Experimental dermatology · 2024Review
- Skin Fibrosis and Recovery Is Dependent on Wnt Activation via DPP4.The Journal of investigative dermatology · 2022Article
- Potential Effect of DPP-4 Inhibitors Towards Hepatic Diseases and Associated Glucose Intolerance.Diabetes, metabolic syndrome and obesity : targets and therapy · 2022Review
- SARS-CoV-2-host proteome interactions for antiviral drug discovery.Molecular systems biology · 2021Article
- Saxagliptin protects against diabetic nephropathy by inhibiting caspase 3/PARP-1-dependent nephrocyte apoptosis.Experimental and therapeutic medicine · 2021Article
- Molecular prospect of type-2 diabetes: Nanotechnology based diagnostics and therapeutic intervention.Reviews in endocrine & metabolic disorders · 2021Review
- Mining the Biomarker Potential of the Urine Peptidome: From Amino Acids Properties to Proteases.International journal of molecular sciences · 2021Review
- Excessively Enlarged Mitochondria in the Kidneys of Diabetic Nephropathy.Antioxidants (Basel, Switzerland) · 2021Review
- Renoprotective Effects of Incretin-Based Therapy in Diabetes Mellitus.BioMed research international · 2021Review
- MicroRNA-30/Cx43 axis contributes to podocyte injury by regulating ER stress in diabetic nephropathy.Annals of translational medicine · 2020Article
- Gemigliptin Inhibits Interleukin-1β-Induced Endothelial-Mesenchymal Transition via Canonical-Bone Morphogenetic Protein Pathway.Endocrinology and metabolism (Seoul, Korea) · 2020Article
- Possibility of pharmacokinetic drug interaction between a DPP-4 inhibitor and a SGLT2 inhibitor.Translational and clinical pharmacology · 2020Review
- Soluble Dipeptidyl Peptidase-4 Induces Fibroblast Activation Through Proteinase-Activated Receptor-2.Frontiers in pharmacology · 2020Article
- Effect of Anagliptin versus Sitagliptin on Inflammatory Markers: Sub-Analysis from the REASON Trial.Diabetes, metabolic syndrome and obesity : targets and therapy · 2020Article
- Gemigliptin Attenuates Renal Fibrosis Through Down-Regulation of the NLRP3 Inflammasome.Diabetes & metabolism journal · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic nephropathy (DN) is the most common cause of end-stage kidney disease worldwide and is associated with increased morbidity and mortality in patients with both type 1 and type 2 diabetes. Recent evidence revealed that dipeptidyl peptidase-4 (DPP-4) inhibitors may exhibit a protective effect against DN. In fact, the kidney is the organ where the DPP-4 activity is the highest level per organ weight. A preclinical analysis revealed that DPP-4 inhibitors also ameliorated kidney fibrosis. In this review, we analyzed recent reports in this field and explore the renoprotective effects and possible mechanism of the DPP-4 inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.